SUPERNUS PHARMACEUTICALS, INC. (SUPN)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue Quarterly

0 80M 160M 240M Q3 '16: 56.8M Q4 '16: 62.4M Q1 '17: 57.6M Q2 '17: 75.8M Q3 '17: 80.4M Q4 '17: 88.4M Q1 '18: 90.4M Q2 '18: 99.5M Q3 '18: 103M Q4 '18: 115.9M Q1 '19: 85.5M Q2 '19: 104.7M Q3 '19: 102.1M Q4 '19: 100.4M Q1 '20: 95M Q2 '20: 126.7M Q3 '20: 155.1M Q4 '20: 143.6M Q1 '21: 130.9M Q2 '21: 141.3M Q3 '21: 148.5M Q4 '21: 159.1M Q1 '22: 152.5M Q2 '22: 170.1M Q3 '22: 177.4M Q4 '22: 167.3M Q1 '23: 153.8M Q2 '23: 135.6M Q3 '23: 153.9M Q4 '23: 164.3M Q1 '24: 143.6M Q2 '24: 168.3M Q3 '24: 175.7M Q4 '24: 174.2M Q1 '25: 149.8M Q2 '25: 165.5M Q3 '25: 192.1M Q4 '25: 211.6M Q1 '26: 207.7M Q2 '26: 219.1M Q3 '17 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Gross Profit Quarterly

0 70M 140M 210M Q1 '17: 54.6M Q2 '17: 72M Q3 '17: 76.1M Q4 '17: 84.3M Q1 '18: 87.2M Q2 '18: 95.9M Q3 '18: 98.8M Q4 '18: 111.7M Q1 '19: 81.8M Q2 '19: 100.7M Q3 '19: 97.3M Q4 '19: 96.3M Q1 '20: 90.8M Q2 '20: 118.3M Q3 '20: 133.7M Q4 '20: 125M Q1 '21: 116M Q2 '21: 116.3M Q3 '21: 130.4M Q1 '22: 134.6M Q2 '22: 149.6M Q3 '22: 151.5M Q4 '22: 144.4M Q1 '23: 130.3M Q2 '23: 114.5M Q3 '23: 134.3M Q4 '23: 144.7M Q1 '24: 127.3M Q2 '24: 150.4M Q3 '24: 158.1M Q4 '24: 148.1M Q1 '25: 134.1M Q2 '25: 148.6M Q3 '25: 173.1M Q4 '25: 188.6M Q1 '26: 184.3M Q2 '26: 185.4M Q2 '17 Q3 '18 Q4 '19 Q1 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Revenue minus cost of sales. This filer tags no gross profit of its own..

Operating Income Quarterly

-75M -50M -25M 0 25M 50M 75M Q3 '16: 19.8M Q4 '16: 16.3M Q1 '17: 16.8M Q2 '17: 26.1M Q3 '17: 22.3M Q4 '17: 34.3M Q1 '18: 31.4M Q2 '18: 35.7M Q3 '18: 37.5M Q4 '18: 39.9M Q1 '19: 25.4M Q2 '19: 42.6M Q3 '19: 39.7M Q4 '19: 40.8M Q1 '20: 29M Q2 '20: 45.5M Q3 '20: 56.1M Q4 '20: 43M Q1 '21: 13.2M Q2 '21: 34.1M Q3 '21: 32.6M Q4 '21: 6.1M Q1 '22: 2M Q2 '22: 11.3M Q3 '22: -1.5M Q4 '22: 34.3M Q1 '23: 5.2M Q2 '23: -17.6M Q3 '23: 8.1M Q4 '23: -996K Q1 '24: -3.2M Q2 '24: 22.6M Q3 '24: 40.8M Q4 '24: 21.4M Q1 '25: -10.3M Q2 '25: 12.1M Q3 '25: -60.2M Q4 '25: -3.9M Q1 '26: -8.3M Q2 '26: -58M Q3 '17 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Net Income Quarterly

-75M -50M -25M 0 25M 50M 75M Q3 '16: 61.8M Q4 '16: 14.3M Q1 '17: 10.3M Q2 '17: 17.4M Q3 '17: 16M Q4 '17: 13.7M Q1 '18: 26.4M Q2 '18: 30.7M Q3 '18: 28M Q4 '18: 25.9M Q1 '19: 18.3M Q2 '19: 32.7M Q3 '19: 28.9M Q4 '19: 33.1M Q1 '20: 21.5M Q2 '20: 34.7M Q3 '20: 40M Q4 '20: 30.8M Q1 '21: 5.7M Q2 '21: 23.7M Q3 '21: 21.6M Q4 '21: 2.4M Q1 '22: 25.6M Q2 '22: 7.9M Q3 '22: 1.7M Q4 '22: 25.5M Q1 '23: 16.9M Q2 '23: -831K Q3 '23: -16M Q4 '23: 1.2M Q1 '24: 124K Q2 '24: 19.9M Q3 '24: 38.5M Q4 '24: 15.3M Q1 '25: -11.8M Q2 '25: 22.5M Q3 '25: -45.1M Q4 '25: -4.1M Q1 '26: -2.3M Q2 '26: -58.4M Q3 '17 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Cost of Revenue Quarterly

0 15M 30M 45M Q1 '17: 2.9M Q2 '17: 3.9M Q3 '17: 4.3M Q4 '17: 4.2M Q1 '18: 3.3M Q2 '18: 3.7M Q3 '18: 4.2M Q4 '18: 4.2M Q1 '19: 3.7M Q2 '19: 4M Q3 '19: 4.8M Q4 '19: 4.1M Q1 '20: 4.2M Q2 '20: 8.4M Q3 '20: 21.4M Q4 '20: 18.5M Q1 '21: 15M Q2 '21: 25M Q3 '21: 18.1M Q4 '21: 17M Q1 '22: 17.9M Q2 '22: 20.5M Q3 '22: 25.9M Q4 '22: 23M Q1 '23: 23.5M Q2 '23: 21.1M Q3 '23: 19.6M Q4 '23: 19.6M Q1 '24: 16.3M Q2 '24: 17.9M Q3 '24: 17.6M Q4 '24: 26.1M Q1 '25: 15.8M Q2 '25: 16.8M Q3 '25: 19M Q4 '25: 23M Q1 '26: 23.4M Q2 '26: 33.7M Q3 '17 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Operating Cash Flow Quarterly

-70M -35M 0 35M 70M 105M Q3 '16: 28.2M Q4 '16: 24.9M Q1 '17: 13.4M Q2 '17: 25.9M Q3 '17: 39M Q4 '17: 36.3M Q1 '18: 27.1M Q2 '18: 6.6M Q3 '18: 62.4M Q4 '18: 32.8M Q1 '19: 33M Q2 '19: 28.7M Q3 '19: 37.7M Q4 '19: 43.8M Q1 '20: 8.9M Q2 '20: 92M Q3 '20: 5.6M Q4 '20: 31.9M Q1 '21: 36.2M Q2 '21: 46.3M Q3 '21: -4.1M Q4 '21: 48.8M Q1 '22: 4.3M Q2 '22: 71.1M Q3 '22: 13.8M Q4 '22: 27.6M Q1 '23: 49.1M Q2 '23: -18.9M Q3 '23: 35.9M Q4 '23: 45M Q1 '24: 38.4M Q2 '24: 35.6M Q3 '24: 53.5M Q4 '24: 44.4M Q1 '25: 30.6M Q2 '25: 58.5M Q3 '25: -61.7M Q4 '25: 19.9M Q1 '26: 66.5M Q2 '26: -4.8M Q3 '17 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Free Cash Flow Quarterly

-70M -35M 0 35M 70M 105M Q4 '15: 19.1M Q1 '16: -3.4M Q2 '16: 16.2M Q3 '16: 27.8M Q4 '16: 24.6M Q1 '17: 13.1M Q2 '17: 25.4M Q3 '17: 38.6M Q4 '17: 35.6M Q1 '18: 26.9M Q2 '18: 6.3M Q3 '18: 62.3M Q4 '18: 32.8M Q1 '19: 32.8M Q2 '19: 28.7M Q3 '19: 37.2M Q4 '19: 41.8M Q1 '20: 6.4M Q2 '20: 91.4M Q3 '20: 5.4M Q4 '20: 31.7M Q1 '21: 34.7M Q2 '21: 46.3M Q1 '22: 3.5M Q2 '22: 70.5M Q3 '22: 13.7M Q4 '22: 27.6M Q1 '23: 48.8M Q2 '23: -19M Q3 '23: 35.7M Q1 '24: 38.2M Q2 '24: 35.6M Q3 '24: 53.3M Q4 '24: 44.2M Q1 '25: 30.3M Q2 '25: 58.1M Q3 '25: -61.8M Q4 '25: 19.4M Q1 '26: 66.5M Q2 '26: -5.4M Q4 '16 Q1 '18 Q2 '19 Q3 '20 Q2 '22 Q3 '23 Q1 '25 Q2 '26

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 25M 50M 75M Q2 '13: 30.9M Q3 '13: 30.9M Q1 '14: 41.1M Q2 '14: 42.4M Q3 '14: 42.9M Q1 '15: 44.9M Q2 '15: 52.3M Q3 '15: 51.6M Q1 '16: 51.2M Q2 '16: 51.7M Q3 '16: 52M Q1 '17: 52.8M Q2 '17: 53.2M Q3 '17: 53.6M Q1 '18: 53.8M Q2 '18: 54.2M Q3 '18: 54.2M Q1 '19: 54M Q2 '19: 53.9M Q3 '19: 53.8M Q1 '20: 53.6M Q2 '20: 53.6M Q3 '20: 53.8M Q1 '21: 54.2M Q2 '21: 54.7M Q3 '21: 54.3M Q1 '22: 61.4M Q2 '22: 61.4M Q3 '22: 55M Q1 '23: 62.5M Q2 '23: 54.5M Q3 '23: 54.6M Q1 '24: 55.6M Q2 '24: 55.7M Q3 '24: 56M Q1 '25: 55.9M Q2 '25: 56.6M Q3 '25: 56.6M Q1 '26: 57.6M Q2 '26: 58.1M Q3 '14 Q2 '16 Q1 '18 Q3 '19 Q2 '21 Q1 '23 Q3 '24 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-2.70 -1.80 -0.90 0.00 0.90 1.80 2.70 Q3 '16: 1.58 Q4 '16: 1.70 Q1 '17: 1.81 Q2 '17: 1.95 Q3 '17: 1.06 Q4 '17: 1.06 Q1 '18: 1.36 Q2 '18: 1.61 Q3 '18: 1.84 Q4 '18: 2.06 Q1 '19: 1.91 Q2 '19: 1.95 Q3 '19: 1.97 Q4 '19: 2.11 Q1 '20: 2.17 Q2 '20: 2.21 Q3 '20: 2.41 Q4 '20: 2.36 Q1 '21: 2.07 Q2 '21: 1.85 Q3 '21: 1.51 Q4 '21: 0.98 Q1 '22: 1.30 Q2 '22: 1.01 Q3 '22: 0.64 Q4 '22: 1.02 Q1 '23: 0.88 Q2 '23: 0.72 Q3 '23: 0.40 Q4 '23: 0.02 Q1 '24: -0.27 Q2 '24: 0.11 Q3 '24: 1.09 Q4 '24: 1.32 Q1 '25: 1.11 Q2 '25: 1.15 Q3 '25: -0.34 Q4 '25: -0.68 Q1 '26: -0.51 Q2 '26: -1.92 Q3 '17 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.